Pre-infection HDL-cholesterol levels and mortality among elderly patients infected with SARS-CoV-2

Introduction Sensitive thyroid-stimulating hormone (TSH) assays provide identification of many patients with subclinical hyperthyroidism resulting from excessive production or excessive replacement of thyroid hormone. Subclinical hyperthyroidism is defined by a TSH below normal (suppressed) with normal serum T3 and T4 levels. Subclinical hyperthyroidism is the goal of thyroid hormone therapy in patients with thyroid cancer, solitary thyroid nodules, multinodular or diffuse goiters, or a history of head and neck irradiation. Benefits of TSH suppression in these patients, were thought to exceed the risks of subclinical hyperthyroidism. Subclinical hyperthyroidism also occurs in patients with thyroiditis and those with autoimmune thyroid disease. Other causes of TSH suppression, such as use of glucocorticoids, severe illness and pituitary dysfunction should be excluded. Material and methods This investigation included 55 elderly patients with subclical hyperthyroidism in order to establish the type and degree of lipid abnormalities and effects of therapy with antithyroid drugs (methimazole 10 mg/day) during three months. These patients presented with no or minimal symptoms of thyroid hormone excess, but 56% of patients experienced atrial fibrillation and cardiac hypertrophy. Results Levels of serum cholesterol, LDL-cholesterol and HDL-cholesterol were decreased. We found a significant increase of serum cholesterol, LDL-cholesterol and HDL-cholesterol levels after treatment. Discussion and Conclusion Subclinical hyperthyroidism in elderly individuals is difficult to diagnose because it may present only with cardiac manifestations including atrial fibrillation and cardiac hypertrophy. There is general agreement that measurement of serum TSH is the most sensitive indicator of thyroid hormone activity in its target tissues. Patients with subclinical hyperthyroidism tend to have low serum total cholesterol, LDL-cholesterol anf HDL-cholesterol levels. These values increase after treatment. Most patients with subclinical hyperthyroidism should be treated with antithyroid drugs to prevent cardiovascular complications and bone loss, particulary among postmenopausal women.

Download Full-text

The Effects of L-Carnitine Supplementation on Serum Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Current Pharmaceutical Design ◽

10.2174/1381612825666190830154336 ◽

2019 ◽

Vol 25 (30) ◽

pp. 3266-3281 ◽

Cited By ~ 1

Author(s):

Hadis Fathizadeh ◽

Alireza Milajerdi ◽

Željko Reiner ◽

Fariba Kolahdooz ◽

Maryam Chamani ◽

...

Keyword(s):

Serum Lipids ◽

Ldl Cholesterol ◽

Meta Analysis ◽

Hdl Cholesterol ◽

Health Conditions ◽

Carnitine Supplementation ◽

Randomized Controlled ◽

Cholesterol Levels ◽

Vldl Cholesterol ◽

Subgroup Analyses

Background: The findings of trials investigating the effects of L-carnitine administration on serum lipids are inconsistent. This meta-analysis of randomized controlled trials (RCTs) was performed to summarize the effects of L-carnitine intake on serum lipids in patients and healthy individuals. Methods: Two authors independently searched electronic databases including MEDLINE, EMBASE, Cochrane Library, Web of Science, PubMed and Google Scholar from 1990 until August 1, 2019, in order to find relevant RCTs. The quality of selected RCTs was evaluated using the Cochrane Collaboration risk of bias tool. Cochrane’s Q test and I-square (I2) statistic were used to determine the heterogeneity across included trials. Weight mean difference (SMD) and 95% CI between the two intervention groups were used to determine pooled effect sizes. Subgroup analyses were performed to evaluate the source of heterogeneity based on suspected variables such as, participant’s health conditions, age, dosage of L-carnitine, duration of study, sample size, and study location between primary RCTs. Results: Out of 3460 potential papers selected based on keywords search, 67 studies met the inclusion criteria and were eligible for the meta-analysis. The pooled results indicated that L-carnitine administration led to a significant decrease in triglycerides (WMD: -10.35; 95% CI: -16.43, -4.27), total cholesterol (WMD: -9.47; 95% CI: - 13.23, -5.70) and LDL-cholesterol (LDL-C) concentrations (WMD: -6.25; 95% CI: -9.30, -3.21), and a significant increase in HDL-cholesterol (HDL-C) levels (WMD: 1.39; 95% CI: 0.21, 2.57). L-carnitine supplementation did not influence VLDL-cholesterol concentrations. When we stratified studies for the predefined factors such as dosage, and age, no significant effects of the intervention on triglycerides, LDL-C, and HDL-C levels were found. Conclusion: This meta-analysis demonstrated that L-carnitine administration significantly reduced triglycerides, total cholesterol and LDL-cholesterol levels, and significantly increased HDL-cholesterol levels in the pooled analyses, but did not affect VLDL-cholesterol levels; however, these findings were not confirmed in our subgroup analyses by participant’s health conditions, age, dosage of L-carnitine, duration of study, sample size, and study location.

Download Full-text

Ser447stopMutation in Lipoprotein Lipase Is Associated With Elevated HDL Cholesterol Levels in Normolipidemic Males

Arteriosclerosis Thrombosis and Vascular Biology ◽

10.1161/01.atv.17.3.595 ◽

1997 ◽

Vol 17 (3) ◽

pp. 595-599 ◽

Cited By ~ 44

Author(s):

Jan Albert Kuivenhoven ◽

Björn E. Groenemeyer ◽

Jolanda M. A. Boer ◽

Paul W. A. Reymer ◽

Riteke Berghuis ◽

...

Keyword(s):

Lipoprotein Lipase ◽

Hdl Cholesterol ◽

Cholesterol Levels

Download Full-text

Passive Cigarette Smoking and Reduced HDL Cholesterol Levels in Children With High-Risk Lipid Profiles

Circulation ◽

10.1161/01.cir.96.5.1403 ◽

1997 ◽

Vol 96 (5) ◽

pp. 1403-1407 ◽

Cited By ~ 45

Author(s):

Ellis J. Neufeld ◽

Michele Mietus-Snyder ◽

Alexa S. Beiser ◽

Annette L. Baker ◽

Jane W. Newburger

Keyword(s):

High Risk ◽

Cigarette Smoking ◽

Hdl Cholesterol ◽

Lipid Profiles ◽

Cholesterol Levels

Download Full-text

Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter: effect on plasma HDL-cholesterol levels.

The Journal of Lipid Research ◽

10.1016/s0022-2275(20)39972-7 ◽

1994 ◽

Vol 35 (7) ◽

pp. 1292-1296

Author(s):

D E Barre ◽

R Guerra ◽

R Verstraete ◽

Z Wang ◽

S M Grundy ◽

...

Keyword(s):

Genetic Analysis ◽

Gene Promoter ◽

Hdl Cholesterol ◽

Human Apolipoprotein ◽

Promoter Effect ◽

Cholesterol Levels ◽

Apolipoprotein A ◽

I Gene

Download Full-text

Evaluation of remnant cholesterol levels and monocyte-to-hdl-cholesterol ratio in south asian patients with acute coronary syndrome

Nutrition Metabolism and Cardiovascular Diseases ◽

10.1016/j.numecd.2021.04.007 ◽

2021 ◽

Author(s):

Vincenzo Sucato ◽

Giuseppe Coppola ◽

Gabriella Testa ◽

Francesco Amata ◽

Marco Martello ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

South Asian ◽

Hdl Cholesterol ◽

Cholesterol Ratio ◽

Coronary Syndrome ◽

Asian Patients ◽

Cholesterol Levels ◽

Remnant Cholesterol

Download Full-text

Low levels of soluble TWEAK, indicating on-going inflammation, were associated with depression in type 1 diabetes: a cross-sectional study

BMC Psychiatry ◽

10.1186/s12888-020-02977-3 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Eva O. Melin ◽

Jonatan Dereke ◽

Magnus Hillman

Keyword(s):

Cardiovascular Disease ◽

Type 1 Diabetes ◽

Goodness Of Fit ◽

Hdl Cholesterol ◽

Cross Sectional ◽

Cholesterol Levels ◽

Increased Risk ◽

Galectin 3 ◽

Low Levels

Abstract Background Low levels of the soluble tumour necrosis factor-like weak inducer of apoptosis (sTWEAK) and depression are linked to cardiovascular disease. Galectin-3, inadequate glycemic control and low high-density lipoprotein (HDL)-cholesterol levels were previously linked to depression in these patients with type 1 diabetes mellitus (T1DM). The main aim was to explore whether sTWEAK was associated with depression. A secondary aim was to explore diabetes related variables associated with low sTWEAK. Methods Cross-sectional design. T1DM patients (n = 283, men 56%, age18–59 years) were consecutively recruited from one specialist diabetes clinic. Depression was defined as Hospital Anxiety and Depression Scale-Depression sub scale ≥8 points. Blood samples, anthropometrics and blood pressure were collected, supplemented with data from electronic health records. Enzyme linked immunosorbent assays were used to measure sTWEAK and galectin-3. Low sTWEAK was defined as < 7.2 ng/ml and high galectin-3 as ≥2.6 ng/ml. Multiple logistic regression analyses were performed, calibrated and validated for goodness of fit. We adjusted for age, sex, diabetes duration, galectin-3, metabolic variables, serum-creatinine, smoking, physical inactivity, medication, and cardiovascular complications. Results For 29 depressed versus 254 non-depressed patients the prevalence rates were for low sTWEAK: 93 and 68% (p = 0.003) and for high galectin-3: 34 and 13% (p = 0.005) respectively. HDL-cholesterol levels were lower for the depressed (p = 0.015). Patients with low sTWEAK versus high sTWEAK had lower usage of continuous subcutaneous insulin infusion (CSII) (6% versus 17%, p = 0.005). Low sTWEAK (adjusted odds ratio (AOR) 9.0, p = 0.006), high galectin-3 (AOR 6.3, p = 0.001), HDL-cholesterol (per mmol/l) (AOR 0.1, p = 0.006), use of antidepressants (AOR 8.4, p < 0.001), and age (per year) (AOR 1.05, p = 0.027) were associated with depression. CSII (AOR 0.3, p = 0.003) and depression (AOR 7.1, p = 0.009) were associated with low sTWEAK. Conclusions Lower levels of sTWEAK and HDL-cholesterol and higher levels of galectin-3 were independently associated with depression in T1DM. These factors might all contribute to the increased risk for cardiovascular disease and mortality previously demonstrated in patients with depression. CSII (inversely) and depression were independently associated with low sTWEAK levels.

Download Full-text